AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03801967
Drug: AZD9977
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized participants will receive oral dose of AZD9977.
Trial: NCT03801967
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized participants will receive oral dose of matching placebo.
Trial: NCT00629278
Drug: aromatase inhibition therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00629278
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00629278
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00629278
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00974142
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fifteen patients will receive will receive placebo.
Trial: NCT00007592
Drug: Chlorthalidone
RxNorm normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01120366
Drug: Tocilizumab plus methotrexate
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab 8mg/kg 4weeks (i.v.) plus methotrexate up to 52weeks.The dosage of MTX will be fixed at least 24 weeks from the start of the study.
Trial: NCT04414995
Drug: Paracetamol injection and Ibuprofen injection
RxNorm normalized name: codeine and paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of combination acetaminophen and ibuprofen to reduce morphine requirement inpatient after Total knee arthroplasty
Trial: NCT00028483
Drug: cBR96-doxorubicin immunoconjugate
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04414995
Drug: Ibuprofen Injection and normal saline
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of ibuprofen and normal saline to reduce morphine requirement inpatient after Total knee arthroplasty
Trial: NCT00743444
Drug: AZD3355
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 65 mg capsules, oral, 3 single doses
Trial: NCT00743444
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules, oral, 3 single doses
Trial: NCT01269749
Drug: ATD Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Characteristics of study population. We will recruit a total of 150 patients diagnosed with GD younger than 18 years of age. All subjects are to be treated with antithyroid drugs (ATDs). In this trial, children will not be randomized to treatment, but will be treated per physician prescribed care. To ensure an equal distribution of age and gender between the two groups of children, we stratify enrollment by gender (male vs. female) and age (5-10 yrs, 10-15 yrs, 15-18 yrs).
Trial: NCT00092105
Drug: Comparator: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01307319
Drug: BDP HFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BDP (beclomethasone dipropionate) HFA (hydrofluoroalkane) nasal aerosol administered as a single actuation in each nostril daily for the 15 day treatment period. Each actuation contains either 40 or 80 mcg for a total daily dose of either 80 or 160 mcg depending upon the assigned treatment arm.
Trial: NCT01307319
Drug: Placebo nasal aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo formulated as a nasal aerosol spray and administered as a single actuation in each nostril daily for the 15 day treatment period.
Trial: NCT02217163
Drug: Carfilzomib, , Cyclophosphamide, Dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carfilzomib is administered intraveneously over 30 minutes. For cycle 1 only, Carfilzomib is administered at 20mg/m2 on Day 1 and 2, dose will be escalated to 36mg/m2 on Day 8,9,15 and 16 of the 28-days cycle. Patients who tolerate the 36mg/m2 dose are kept at this dose for the subsequent cycles on Day 1,2,8,9,15,16 on a 28 days cycle. Cyclophosphamide is given at a fixed dose of 500mg once per week orally, along with dexamethasone which is given on the days of Carfilzomib administration, 30 minutes to 4 hours prior to Carfilzomib infusion.
Trial: NCT03622008
Drug: FEP-TAZ 4 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FEP-TAZ 4 g (2 g cefepime + 2 g tazobactam) IV treatments as a q8h infusion (90 min) regimen for 10 days
Trial: NCT00806533
Drug: HES 130 / 0.42 (Venofundin 6%, Tetraspan 6%)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solution for intravenous infusion applied according to SmPC
Trial: NCT02204930
Drug: PeproStat
RxNorm normalized name: Sus scrofa prostate preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A solution of PeproStat containing up to 9.25mg protein soaked immediately prior to use onto a Gelita-Spon® gelatin sponge.
Trial: NCT01412177
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intratympanic injection of placebo
Trial: NCT00008008
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02773381
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration once-daily.
Trial: NCT05490017
Drug: KP104
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive KP104 intravenous (IV) dose approximately for 1 hour or subcutaneous (SC) dose.
Trial: NCT05490017
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching placebo which is KP104 vehicle containing sodium phosphate, sodium chloride, and L-Lysine Hydrochloride (L-Lys-HCL).
Trial: NCT00769886
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop of vehicle in study eye at visit 3 and visit 4.
Trial: NCT00230399
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00230399
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00851357
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo nicotine patch
Trial: NCT01288755
Drug: TMC278
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One 25 mg tablet, once daily, for 11 days (TrtA and C)
Trial: NCT02600520
Drug: SRP with placebo gel LDD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After SRP, placebo gel was delivered subgingivally into the pocket
Trial: NCT03567369
Drug: Traumeel S
RxNorm normalized name: Traumeel S Injection Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traummel S 2,2 mg/mL
Trial: NCT03053388
Drug: Nitric Oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitric Oxide given via inhalation in cycles
Trial: NCT02038868
Drug: ASP4901
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT02038868
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT00396513
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00396513
Drug: Simvastatin and Metformin
RxNorm normalized name: simvastatin and ezetimibe
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01389076
Drug: Low Dose Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate is an antifolate drug. It interferes with cells' ability to copy their DNA. This mainly affects cells that are dividing frequently, such as immune system cells and cancer cells. Methotrexate will be used in this study to try to prevent the occurrence of HAMA by limiting your body's ability to produce anti mouse antibodies.
Trial: NCT00003899
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01517932
Drug: saline placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In this arm,midazolam(0.03-0.05mg/kg), propofol(1.5-2.5mg/kg),sufentanil(0.6-0.82μg/kg )and rocuronium(0.8-1.0mg/kg) were used in anesthesia induction.~Anaesthesia was maintained with propofol（4-6mg kg-1h-1），remifentanil (0.1-0.2 μg kg-1 min-1）and sevoflurane（1%).Propofol was titrated to maintain intraoperative Narcotrend values between 20 and 46.~Patients in this arm received saline placebo of the same volume i.v. during 10 minutes 1 hour before the end of surgery
Trial: NCT00547274
Drug: MK0767
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00434681
Drug: paracetamol 4.8% paediatric oral suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00900510
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04139629
Drug: treatment of infertility with ART
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COS in gonadotropin-releasing hormone (GnRH) antagonist protocol with IVF/ICSI, fresh ET and, if no pregnancy occurred, frozen/thawed ET (for all embryos resulting from this COS) will be performed.
Trial: NCT02998931
Drug: Glutamin
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enteral Glutamine 0.3g/kg/day powdered glutamine to be mixed in with water and given via nasogastric tube q4 hrs
Trial: NCT02712008
Drug: REGN910-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-formulation for intravitreal (IVT) injection consisting of REGN910 (nesvacumab) and REGN3 (aflibercept)
Trial: NCT00496015
Drug: Paracetamol.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Body weight of \< 7 kg: none; Body weight of ≥ 7 kg to \< 9 kg : 3 suppositories of 125 mg to be administered at 8h intervals after vaccination. Body weight of ≥ 9 kg: 4 suppositories of 125 mg to be administered at 6h intervals after vaccination.
Trial: NCT01590979
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two times a day, 12 hour intervals
Trial: NCT00138749
Drug: SS-RBX
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01865266
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01153165
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in the control group will receive a matched placebo. At week 4 participants will be assessed for response to treatment. If no response, dose of placebo will be increased to 40mgs for the remaining 8 weeks of the study. Patients who respond will remain on 20mgs for remaining 8 weeks.
Trial: NCT00276510
Drug: EGb 761® (Tanakan®)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg, 1 tablet twice a day, oral route, during 5 years.
Trial: NCT02210000
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camicinal matching placebo is available as tablet to be taken orally with 100mL of water in the morning
Trial: NCT01199198
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo by mouth once a day for 14 days.
Trial: NCT02123134
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphate buffered saline placebo for injection
Trial: NCT01776658
Drug: SYL1001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ocular topical administration of SYL1001 for 10 consecutive days
Trial: NCT01776658
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ocular topical administration of placebo for 10 consecutive days
Trial: NCT04125563
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soft gel capsules filled with placebo - sorbitol and colorant.
Trial: NCT01227798
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline
Trial: NCT04120350
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3.5g/m2 intravenous infusion for 4 hours in d1, every 21 days for 1 cycle. 6 cycles will be prescribed as protocol
Trial: NCT00883779
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: po on days 15-28 of each 4 week cycle until disease progression
Trial: NCT01191723
Drug: MAP0004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.0mg orally inhaled MAP0004 administered in Treatment B as per protocol
Trial: NCT01191723
Drug: Inhaler Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for Inhaler administered in Treatments A and C
Trial: NCT01191723
Drug: Placebo Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for Moxifloxacin administered in Treatment B and Treatment C
Trial: NCT01885156
Drug: Naftin 1% Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topically applied once a day
Trial: NCT01885156
Drug: Placebo Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topically applied once a day
Trial: NCT03226717
Drug: Antiviral agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combination therapy consists of Sofosbuvir,daclatasvir and ribavirin
Trial: NCT02972060
Drug: ADT
RxNorm normalized name: Radtue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADT by means of LHRH antagonist for 24 weeks or by LHRH agonist therapy for 24 weeks with 4 weeks of anti-androgen to prevent flare.~This includes leuprolide, goserelin, triptorelin, and degarelix. Beyond week 24, the treatment will be left to the discretion of the treating physician.
Trial: NCT02091817
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be given to control group and experimental group as well.
Trial: NCT01918124
Drug: Cisplatin and Doxorubicin and Cyclophosphamide
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Four courses of cisplatin (50mg/m2) and doxorubicin (60mg/m2) and cyclophosphamide (600mg/m2) chemotherapy given at 3 week intervals following completion of radiotherapy.
Trial: NCT01957215
Drug: Indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical indomethacin
Trial: NCT01670825
Drug: Corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
DrugBank: Corticosterone (DB04652)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid and local anesthetic injection plus sham pulsed radiofrequency over each affected occipital nerve
Trial: NCT00150514
Drug: Oralgen
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04129619
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT02631096
Drug: ARB-001467
RxNorm normalized name: revakinagene taroretcel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An IV infusion of ARB-001467
Trial: NCT01685060
Drug: LDK378
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceritinib/LDK378 was supplied as 150 mg hard gelatin capsules and were administered orally, once-daily at a dose of 750 mg on a continuous dosing schedule (5 x 150 mg capsules).
Trial: NCT00547989
Drug: standard anaesthesia (bupivacaine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local infiltration with bupivacaine and Piritramide and Paracetamol as postoperative analgesic, and ondansetron as required
Trial: NCT01091675
Drug: Etoricoxib
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib 90 mg/day/PO during 4 weeks Positive response to the therapy (in investigator opinion): Ongoing treatment with 90 mg/day/PO until 24 weeks.
Trial: NCT02038790
Drug: Zubsolv sublingual tablets
RxNorm normalized name: Zubsolv Sublingual Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single Zubsolv sublingual tablet containing 5.7mg buprenorphine and 1.4mg naloxone taken sublingually on either Day 0 or Day 1, depending on randomized treatment arm assignment. Study drug will be administered by designated qualified study personnel at the site in the morning prior to 9:00 a.m. under fasting conditions.
Trial: NCT02941042
Drug: NNC9204-1177
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose administered subcutaneously ( s.c. under the skin)
Trial: NCT02941042
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose administered subcutaneously ( s.c. under the skin)
Trial: NCT00948194
Drug: Nitric Oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhalation - 40 ppm, at the initiation of anesthesia to the end of surgery
Trial: NCT01821573
Drug: injection of NaCl 0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator group: injection of NaCl 0.9%:~* 3 ml of NaCl 0.9% in rectus femoris in 3 points~* 1.4 ml of NaCl 0.9% in medial gastrocnemius in 1 point~* 1.4 ml of Nacl 0.9% in lateral gastrocnemius in 1 point~* 1.2 ml of NaCl 0.9% in soleus in 3 points
Trial: NCT00002805
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002805
Drug: therapeutic hydrocortisone
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03603327
Drug: Direct acting anti-viral agents
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care for Hepatitis C treatment
Trial: NCT02253927
Drug: BILR 355 - D1
RxNorm normalized name: PHOSPHOLIPASE D1
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02253927
Drug: BILR 355 - D3
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02203175
Drug: fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: before the anesthesia induction 50 mcgr fentanyl
Trial: NCT04148872
Drug: Chemodenervation (4 months)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A neurotoxin that temporarily reduces muscle activity and minimizes the effects of uncoordinated muscle.
Trial: NCT03875872
Drug: inhalation anaesthetics
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who had surgeries and were anaesthetized via inhalation at Queen Mary Hospital, Hong Kong from Jan 2015 to Dec 2017
Trial: NCT00348712
Drug: inhaled human insulin
RxNorm normalized name: insulin, regular, human Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treat-to-target dose titration scheme, inhalation.
Trial: NCT02647307
Drug: DS-1040b
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 12-hour intravenous infusion of DS-1040b (20 mg)
Trial: NCT02259764
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00784459
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with Placebo, IV
Trial: NCT03324776
Drug: Afrezza Inhalant Product
RxNorm normalized name: Afrezza Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mealtime Ultra-Rapid Acting Insulin
Trial: NCT00960063
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00960063
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04363203
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin: 2x250mg by mouth (PO) in the AM on Day 1, followed by 250mg PO every day on Days 2-5.
Trial: NCT02737605
Drug: Oral Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching placebo orally.
Trial: NCT02737605
Drug: Intranasal Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive intranasal placebo (1 spray in each nostril at 0, 5, and 10 minutes).
Trial: NCT04258761
Drug: 10XB-101 Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active test article
Trial: NCT04363203
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in pill packs identical to study drugs
Trial: NCT03561675
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
Trial: NCT01847352
Drug: Intravenous administration of ferric carboxymaltose
RxNorm normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous administration of ferric carboxymaltose 15mg/kg up to a maximum dose of 1000mg
Trial: NCT01222845
Drug: Test meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Porridge made from rolled, or pinhead oats providing 50 g of carbohydrate
Trial: NCT00424099
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One capsule, orally every two hours as needed up to a maximum of 4 capsules per day for a period of 14 days.
Trial: NCT02570503
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ketorolac (30mg/ml)- 1 ml
Trial: NCT02570503
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: epinephrine (1mg/ml)-1ml